In addition to wild-type CFTR gene delivery strategy, CFTR gene editing with CRISPR/Cas9 technology emerged as a promising therapeutic option for CF patients (Hodges and Conlon, 2019). This evidence concerns the gene CFTR and cystic fibrosis.